Pay in 4 interest-free payments of $5.64 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
RGN-352 was shown to be safe and well-tolerated with no serious drug-related adverse events reported (PMID: 20536472) Phase 2 AMI trial (incomplete): RegeneRx designed a Phase 2 proof-of-concept trial (NCT01311518) to evaluate RGN-352 in approximately 75 patients with acute ST-segment elevation myocardial infarction (heart attack)
From speeding up recovery and managing inflammation to supporting digestive health, enhancing cognitive function, and promoting long-term vitality, BPC-157 offers a range of benefits that can significantly impact your overall well-being
Recommended disposal within 28 days after opening when used in controlled environments
Karen Thampoe, Owner and Medical Director, ensures that all treatments are guided by medical expertise and patient-focused care
Rotate injection sites to avoid lipohypertrophy (fat-pad buildup)
Consulting a healthcare provider can help tailor the best treatment plan
US$ 24.51
US$ 29.72
US$ 21.15
US$ 21.19
US$ 25.82
